Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

0
Player Avatar chopchop0 (74.52) Submitted: 8/19/2011 10:03:27 AM : Outperform Start Price: $12.04 DNDN Score: -56.38

The product is good. The marketing needs work

Featured Broker Partners


Advertisement